

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **The United Laboratories International Holdings Limited**

**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 3933)

### **UPDATED INFORMATION ON THE GROUP'S PRODUCT**

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that on 12 April 2023, The United Bio-Technology (Hengqin) Co., Ltd. ("The United Bio-Technology"), a wholly-owned subsidiary of the Company, received the Notice of Approval of Clinical Trial (Reference No.: 2023LP00617) issued by China National Medical Products Administration regarding the insulin degludec and liraglutide injection.

The insulin degludec and liraglutide injection consists of insulin degludec, a basal insulin, and liraglutide, a human glucagon-like peptide-1 (GLP-1) analog, with complementary effects to improve blood glucose control. It can be used in adult Type 2 diabetes patients with poor blood glucose control. After the insulin degludec and liraglutide injection enters the human blood circulation, the blood glucose level can be effectively controlled in the whole day by injection once a day in different target organs through a complementary mechanism of action. The Company is the first enterprise in China to obtain clinical approval for this biosimilar.

The approval will further enrich the Company's product portfolio in the field of diabetes treatment and accelerate the Company's strategic layout in the field of chronic diseases. In the future, the Company will continue to commit itself to the research and development of new products, and focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, with a view of creating more benefits for the Company and its shareholders.

By Order of the Board

**The United Laboratories International Holdings Limited**

**Tsoi Hoi Shan**

*Chairman*

Hong Kong, 14 April 2023

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon and Prof. Song Ming as independent non-executive directors.